Amsterdam
,
Netherlands
25 - 28 August 2023
European Society of Cardiology (ESC 2023)
Presentation schedule and materials
The congress symposium is no longer available
Friday, 25 August 2023
POSTER
Dyslipidaemia and its management in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study
Hani Sabbour1; Naji Alamuddin2; Fatheya Alawadi3; Hessa Alkandari4; Wael Almahmeed1; Samir H. Assaad-Khalil5; Tarhan Cinar6; Jihad Haddad7; Lise Lotte N. Husemoen8; Landman Lombard9; Rayaz A Malik10; Mary Ngome6; Sam Salek11; Gourav Yadav6; Subodh Verma12
POSTER
Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide
Nikolaus Marx1; John E Deanfield2; Sofia Gerward3; G Kees Hovingh3; Oscar Plunde3; Richard E Pratley4; Jacob Stærk-Østergaard3; Vlado Perkovic5
POSTER
Cardioprotective pharmacotherapy in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study
Subodh Verma1; Naji Alamuddin2; Fatheya Alawadi3; Hessa Alkandari4; Wael Almahmeed5; Samir H. Assaad-Khalil6; Tarhan Cinar7; Jihad Haddad8; Lise Lotte N. Husemoen9; Landman Lombard10; Rayaz A Malik11; Mary Ngome7; Hani Sabbour5; Gourav Yadav7; Sam Salek12
ORAL PRESENTATION
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
Mikhail N. Kosiborod1; Steen Z Abildstrøm2; Barry A Borlaug3; Javed Butler4; Søren Rasmussen2; Melanie Davies5; G. Kees Hovingh2; Dalane Kitzman6; Marie L Lindegaard2; Daniél Vega Møller2; Sanjiv J Shah7; Marianne Bach Treppendahl2; Subodh Verma8; Mark C Petrie9
Monday, 28 August 2023
ORAL PRESENTATION
Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
O. Kobo1; MA. Cavender2; S. Hinsch Gylvin*3; AB. Kuhlman3; S. Rasmussen3; S. Verma4
ORAL PRESENTATION
Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)
John E Deanfield1; John B Buse2; Sofia Gerward3; G Kees Hovingh3; A Michael Lincoff4; Oscar Plunde3; Jorge Plutzky5; Jacob Stærk-Østergaard3; Darren K McGuire6
Keywords